Rituximab Combined With Chemotherapy in Burkitt's Lymphoma
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to prove the efficacy of the following new regimen
treatment:
- Administration of anti-CD20 (Rituximab) combined with chemotherapy.
- Combined treatment with high doses of methotrexate and high doses of cytarabine with
conventional cytostatics (block C)
- Prophylactic administration of G-CSF after all chemotherapy cycles
- local irradiation after 6 cycle if CNS was affected or if there are residual tumour